α<sub>1D</sub>-AR与男性LUTS相关性的研究进展

涂红坚; 谷宝军

doi:10.13201/j.issn.1001-1420.2014.02.027

α_1D-AR与男性LUTS相关性的研究进展

涂红坚¹,
谷宝军^2, ,

- 1. 苏州大学医学部(江苏苏州, 215006);
- 2. 上海交通大学附属第六人民医院泌尿外科
基金项目:
国家自然科学基金项目(编号30872568)

上海市科委启明星追踪项目(编号09QH1402000)

详细信息

通讯作者: 谷宝军, E-mail:baojun70@sohu.com

中图分类号: R691

收稿日期: 2013-10-23

Research progress of relationship between α_1D-adrenoceptor and male lower urinary tract symptoms

TU Hongjian¹,
GU Baojun^2, ,

- 1 Medical College of Soochow University, Suzhou, Jiangsu, 215006, China;
- 2 Department of Urology, Shanghai 6th People's Hospital, Shanghai Jiaotong University

More Information

Corresponding author: GU Baojun, E-mail: baojun70@sohu.com

Received Date: 23 October 2013

摘要

摘要: 下尿路症状 (LUTS) 包括储尿症状和排尿症状两方面, 严重时明显影响患者的生活质量。α1D肾上腺素能受体 (α1D-AR) 与男性LUTS密切相关, 本文结合基础研究, 分别阐述了α1D-AR分子结构、动物模型中膀胱出口梗阻对α1D-AR表达水平的影响以及α1D-AR对排尿功能及传入神经活性的调节, 再根据临床研究, 就α1DAR在梗阻膀胱中的功能性反应及其在人膀胱中的作用、前列腺增生 (BPH) 患者中α1D-AR表达水平的差异对药物反应的预测等问题的研究作一综述。
- 储尿症状 /
- 排尿症状 /
- α_1D-AR /
- 排尿功能紊乱 /
- 膀胱
Abstract: Lower urinary tract symptoms (LUTS) consist of storage symptoms and voiding symptoms, and they severely affect patients' quality of life, α_1D1D1D1D-AR expression level.Voiding function and afferent nerve activity modulation through α_{1D1D1D

Key words:

storage symptoms
/

voiding symptoms
/

α1D-AR
/

voiding dysfunction
/

bladder}

HTML全文

参考文献(20)

[1]	García-Sáinz J A, Vázquez-Cuevas F G, Romero-Avila M T.Phosphorylation and desensitization of alpha1 dadrenergic receptors[J].Biochem J, 2001, 353 (Pt 3):603-610.
[2]	García-Sáinz J A, Rodríguez-Pérez C E, Romero-Avila M T.Human alpha-1D adrenoceptor phosphorylation and desensitization[J].Biochem Pharmacol, 2004, 67 (10):1853-1858.
[3]	Hampel C, Dolber P C, Smith M P, et al.Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction[J].J Urol, 2002, 167 (3):1513-1521.
[4]	González Enguita C, Vela Navarrete R, Salcedo de Diego A, et al.Categorization of adrenergic alpha 1receptors in detrusor of patients with obstructive BPH.Initial study on experimental animal model[J].Actas Urol Esp, 2003, 27 (9):684-691.
[5]	Chen Q, Takahashi S, Zhong S, et al.Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor[J].J Urol, 2005, 174 (1):370-374.
[6]	Gu B, Reiter J P, Schwinn D A, et al.Effects of alpha 1 -adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction[J].J Urol, 2004, 172 (2):758-762.
[7]	Dmitrieva N, Zhang G, Nagabukuro H.Increased α_1D adrenergic receptor activity and protein expression in the urinary bladder of aged rats[J].World J Urol, 2008, 26 (6):649-655.
[8]	Wang X J, Matsumoto-Miyai K, Yoshizumi M, et al.Urothelial α_1D receptor is predominantly involved in the adrenergic facilitation of micturition reflex[J].LUTS, 2009, 1 (s1):S10-S14.
[9]	Ishihama H, Momota Y, Yanase H, et al.Activation of α^1D adrenergic receptors in the rat urothelium facilitates the micturition reflex[J].J Urol, 2006, 175 (1):358-364.
[10]	Sugaya K, Nishijima S, Tasaki S, et al.Effects of propiverine and naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats[J].Neurosci Lett, 2007, 429 (2-3):142-146.
[11]	Nomiya M, Yamaguchi O.A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders[J].J Urol, 2003, 170 (2 Pt 1):649-653.
[12]	Kurizaki Y, Ishizuka O, Imamura T, et al.Relation between expression of α (1) -adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms[J].Scand J Urol Nephrol, 2011, 45 (1):15-19.
[13]	Paick J S, Ku J H, Shin J W, et al.alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms:aprospective study of response prediction[J].BJU Int, 2006, 97 (5):1017-1023.
[14]	Yoshida M, Inadome A, Masunaga K, et al.Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia[J].Neurourol Urodyn, 2010, 29 (7):1276-1281.
[15]	Yokoyama O, Aoki Y, Tsujimura A, et al.α (1) -adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume[J].World J Urol, 2011, 29 (2):233-238.
[16]	Watanabe M, Yamanishi T, Mizuno T, et al.Effects of silodosin on lower urinary tract symptoms in patients with benign prostatic hyperplasia:evaluation by frequency/volume chart[J].LUTS, 2010, 2 (1):31-36.
[17]	Nishino Y, Masue T, Miwa K, et al.Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia:a randomized crossover study[J].BJU Int, 2006, 97 (4):747-751.
[18]	Kakizaki H, Tanaka H, Mitsui T, et al.Clinical efficacy of α1-blocker naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia[J].LUTS, 2009, 1 (1):35-39.
[19]	Kojima Y, Sasaki S, Shinoura H, et al.Quantification of α1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients[J].Prostate, 2006, 66 (7):761-767.
[20]	Kojima Y, Sasaki S, Kubota Y, et al.Expression ofα1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selectiveα1-adrenoceptor antagonists in the management of benign prostatic hyperplasia[J].J Urol, 2008, 179 (3):1040-1046.